Biological E. will soon start Phase III trials of its COVID-19 vaccine and plans to produce 75 million to 80 million doses a month from August, its managing director told Reuters.
The timing of this acquisition is fortuitous as it will immediately allow us to expand our capacity to manufacture our investigational COVID-19 vaccine, said the company.